Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04356716 · ClinicalTrials.gov registry record · Phase 2
Sildenafil for Treatment of Choroidal Ischemia
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT04356716 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 22 participants.
The verdict
NCT04356716, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.
Interventions
- DRUG Sildenafil
- OTHER Standard of Care Sildenafil
- DIAGNOSTIC_TEST Ocular Coherence Tomography-Angiography (OCT-A)
- OTHER Visual Acuity (VA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-11-11 |
| Est. Completion | 2020-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04356716
The ClinicalTrials.gov registry entry for NCT04356716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sildenafil is the first listed.
NCT04356716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04356716 about?
NCT04356716 is a clinical study titled "Sildenafil for Treatment of Choroidal Ischemia". The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with here...
What is the current status of trial NCT04356716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-11-11. Estimated completion is 2020-02-18.
What interventions are being tested in trial NCT04356716?
The interventions under investigation include: Sildenafil (DRUG), Standard of Care Sildenafil (OTHER), Ocular Coherence Tomography-Angiography (OCT-A) (DIAGNOSTIC_TEST), Visual Acuity (VA) (OTHER).
Who is sponsoring clinical trial NCT04356716?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.